Galmed Pharmaceuticals prices upsized IPO at $13.50, within the range


Shutterstock photo

Galmed Pharmaceuticals, a clinical-stage biotech with a candidate for liver diseases ( NASH ), raised $38 million by offering 2.8 million shares at $13.50, within the range of $12.00 to $14.00. The company originally planned to offer 2.4 million shares. Galmed Pharmaceuticals plans to list on the NASDAQ under the symbol GLMD. Galmed Pharmaceuticals initially filed confidentially on 12/31/2013. Maxim Group LLC acted as sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
More Headlines for: NASH , GLMD

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by